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Abstract
Myotube apoptosis occurs normally during muscle development and aging but it can lead to destruction of skeletal muscle in
neuromuscular diseases. Therefore, understanding how myotube apoptosis is regulated is important for developing novel
strategies for treatment of muscle loss. We investigated the regulation of apoptosis in skeletal muscle and report a striking
increase in resistance to apoptosis following differentiation. We find mitotic C2C12 cells (myoblast-like cells) are sensitive to
cytosolic cytochrome c microinjection. However, differentiated C2C12 cells (myotube-like cells) and primary myotubes are
markedly resistant. This resistance is due to endogenous X-linked inhibitor of apoptotic protein (XIAP). Importantly, the
selective difference in the ability of XIAP to block myotube but not myoblast apoptosis is not due to a change in XIAP but
rathera decreaseinApaf-1expression.This decreaseinApaf-1linksXIAPtocaspaseactivation anddeath. Ourfindings suggest
that in order for myotubes to die, they may degrade XIAP, functionally inactivate XIAP or upregulate Apaf-1. Importantly, we
identify a role for endogenous Smac in overcoming XIAP to allow myotube death. However, in postmitotic cardiomyocytes,
where XIAP also restricts apoptosis, endogenous Smac was not capable of overcoming XIAP to cause death. These results
show that as skeletal muscle differentiate, they become resistant to apoptosis because of the ability of XIAP to regulate
caspase activation. The increased restriction of apoptosis in myotubes is presumably important to ensure the long term
survival of these postmitotic cells as they play a vital role in the physiology of organisms.
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Introduction
Skeletal muscle is a highly specialized tissue that is unique in its
structure and development. Individual myotubes that comprise
skeletal muscle are derived from mitotic myoblasts which under
the right environmental cues begin to express myogenic markers,
exit the cell cycle and fuse to form long multinucleated myotubes
[1]. While the molecular details of this differentiation process are
well understood, very little is known about whether fundamental
biological processes such as apoptosis are altered during this
process of differentiation. Understanding this phenomenon is
important because, following the developmental period, muscle
loss can have deleterious effects. For example, conditions such as
muscular dystrophies, neurogenic muscular atrophy and mito-
chondrial myopathies result in skeletal muscle death involving
apoptosis [2].
Apoptosis is a genetically regulated, evolutionarily conserved
form of cell death. It is characterized by the activation of caspase
proteases that cleave numerous substrates within the cell to cause
thedemiseofthe cell[3].Intheintrinsicpathwayofapoptosiswhich
can be activated by various stressors such as growth factor
withdrawal, ER stress and DNA damage, signaling pathways
converge upon the proapoptotic proteins Bax and Bak. This causes
their activation and translocation to the mitochondria where they
release cytochrome c from the intermembrane space. Once free in
the cytosol, cytochrome c binds to the adapter protein Apaf-1. This
binding induces a conformational change in Apaf-1 in such a way
that Apaf-1 oligomerizes as well as binds to procaspase 9 to form the
apoptosome complex. Once on the apoptosome, caspase 9 becomes
active and cleaves procaspase 3 into its active form. Active caspase 3
is known as the executioner caspase because it cleaves various
proteins ultimately leading to the death of the cell [4,5].
Recent reports indicate that mitotic myoblasts utilize an
alternative mechanism of activating caspases [6]. Activation of
caspases 9 in these cells occurs independently of Apaf-1 but still
requires release of endogenous Smac from the mitochondria [7,8].
Smac is a mitochondrial intermembrane space protein which acts
as an inhibitor of an antiapoptotic family of proteins known as the
Inhibitor of Apoptotic Proteins (IAPs) [9,10]. IAPs regulate
apoptosis by binding to and inhibiting caspases [11]. Despite our
knowledge of the structure and function of Smac, a critical role for
endogenous Smac in regulating apoptosis has not been discovered
in other primary cells. Importantly, what happens to this pathway
upon differentiation of myoblasts into myotubes is unknown.
Skeletal muscles are known to become more resistant to apoptosis
upon differentiation [12]. However, as most of the studies
examining skeletal muscle apoptosis have focused on whole tissue,
the mechanism for this increased resistance has not been clearly
identified at the cellular level.
In this study, we investigated how isolated myotubes regulate
their caspase activation following differentiation. We report that
myotubes exhibit an increase in their resistance to apoptosis
relative to their mitotic precursor cells. While mitotic C2C12 cells
(mC2C12) die with the introduction of cytochrome c into their
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myotubes do not. This increased resistance is due to endogenous
XIAP. We show that endogenous XIAP is able to selectively block
caspase activation in myotubes not because its levels are increased
in myotubes but rather because the level of Apaf-1 is dramatically
decreased. Importantly, our studies identify endogenous Smac as
having a vital role in overcoming this XIAP inhibition in myotubes
but not cardiomyocytes.
Results
Myotubes develop resistance to cytochrome c-induced
apoptosis upon differentiation
To determine whether cytochrome c-mediated caspase activa-
tion becomes more restricted with skeletal muscle differentiation,
we microinjected cytochrome c in C2C12 cells and myotubes.
Myoblast-like C2C12 (mC2C12) cells were very sensitive to bovine
cytochrome c with almost a complete loss of injected cells within
one hour (Fig. 1a, b). Yeast cytochrome c serves as an ideal control
because unlike mammalian cytochrome c, it is not capable of
binding to Apaf-1, and therefore, cannot activate the apoptosome
[13]. As anticipated, mC2C12 cells injected with yeast cytochrome
c did not die, indicating that microinjection alone was not killing
these cells (Fig. 1a, b). In striking contrast to the mC2C12 cells,
C2C12 cells that had been differentiated for nine days (dC2C12)
did not undergo death when injected with bovine or yeast
cytochrome c (Fig. 1a, b). To examine primary cells, we isolated
murine myoblasts. While the small size of primary myoblasts made
them technically difficult to microinject, we were able to
differentiate them in culture for 14 days into myotubes and inject
these myotubes. Just as seen with the dC2C12 cells, primary
myotubes were markedly resistant to bovine cytochrome c (Fig. 1a).
Together, this data indicated that while mC2C12 cells were
sensitive to cytochrome c induced apoptosis, postmitotic dC2C12
cells and primary myotubes developed resistance.
During differentiation, myoblasts exit the cell cycle and fuse to
form myotubes [1]. To determine at what point myotubes gained
resistance to cytosolic cytochrome c, we injected dC2C12 cells and
primary myotubes at different days of differentiation. Following six
days of differentiation, C2C12 cells still remained sensitive to
cytosolic cytochrome c injections, showing complete apoptosis one
hour after injection. By seven days of differentiation they had
developed some resistance and by nine days, almost all cells
survived cytochrome c injection (Fig. 1c). Likewise, differentiating
primary myotubes also showed a gradual resistance to cytochrome
c. Four days into the differentiation process only 30 % survived
one hour post cytochrome c injection. However, by 11 days this
survival increased to about 60 % and almost complete protection
was seen by 14 days (Fig. 1d). Injecting yeast cytochrome c did not
induce death at any stage of differentiation. These data suggest
that as myotubes differentiate they gradually develop resistance to
cytochrome c and lose their ability to undergo apoptosis in
response to cytochrome c.
Myotube resistance to cytochrome c can be overcome
with the exogenous addition of the IAP inhibitor Smac or
genetic deletion of XIAP
Resistance to cytochrome c has been seen in primary neurons
and cardiomyocytes where it has been linked to the function of
endogenous XIAP [14–16]. To determine if IAPs also play a role
in myotube resistance to cytochrome c, we injected both dC2C12
cells and primary myotubes with the IAP inhibitor Smac. When
cytochrome c and Smac were coinjected into dC2C12 cells or
primary myotubes, it resulted in rapid and complete death (Fig. 2).
Control injections with cytochrome c or Smac alone did not
induce significant death in these cells. To ensure that it was the
IAP inhibiting function of Smac that was responsible for this
action, we also injected cytochrome c into dC2C12 cells with a
mutant form of Smac (MVPI-Smac) carrying a single point
mutation that does not allow it to bind and inhibit IAPs [9]. In
contrast to wildtype Smac (AVPI-Smac), coinjection of cyto-
chrome c and mutant MVPI-Smac did not result in cell death
(Fig. 2a).
These Smac injection experiments suggested that IAPs were in
fact responsible for inhibiting cytochrome c-induced death in
myotubes. Since XIAP has been shown to be the most effective
IAP at inhibiting apoptosis [11], we tested whether endogenous
XIAP was responsible for restricting myotube apoptosis. Myoblasts
were isolated from wildtype and XIAP-deficient mice and
differentiated in culture for 14 days prior to injection with
cytochrome c. In contrast to wildtype myotubes, XIAP-deficient
myotubes were strikingly sensitive to cytochrome c and underwent
apoptosis by two hours following injection (Fig. 2b). XIAP-
deficient myotubes injected with yeast cytochrome c, as a control,
did not die. Taken together, these data suggest that myotubes are
unable to undergo apoptosis in response to cytochrome c due to
the strict control of caspase activation by endogenous XIAP.
Endogenous XIAP effectively restricts cytochrome c-
induced death in myotubes due to reduced Apaf-1 levels
XIAP is a ubiquitously expressed protein [17]. To determine why
postmitotic myotubes have selectively developed this XIAP brake in
apoptosis, we looked at the level of XIAP in these mitotic and
postmitotic cells. We found XIAP levels to be the same in mC2C12
versus dC2C12 and primary myoblasts versus primary myotubes
(Fig. 3a, b). However, we found that Apaf-1 levels were decreased in
both dC2C12 cells and primary myotubes relative to their mitotic
precursors (Fig. 3a, b). Examination of the mRNAlevelsalso showed
a decrease in Apaf-1 in primary myotubes relative to myoblasts
(Fig. 3c). These results lead us to examine whether Apaf-1 was
limiting for caspase activation in myotubes. To test this, we injected
plasmids for Apaf-1 and GFP in dC2C12 cells. Twenty four hours
followinginjections,GFPexpressingcellswereinjectedwithcytosolic
cytochrome c. Expression of Apaf-1 alone in dC2C12 cells did not
induce death and the cells remained resistant to control injection of
yeastcytochromec. In contrast, injection ofbovine cytochromec was
able to induce death in the Apaf-1 overexpressing dC2C12 cells.
Cells injected with vector and GFP showed significantly less death
with bovine cytochrome c (Fig. 3d). Thus, expressing Apaf-1 was
sufficient to allow cytochrome c-mediated death in myotubes.
Together, these results suggest that the decreased levels of Apaf-1
in myotubes results in limited caspase activation, thus allowing
endogenous XIAP to effectively protect against cytochrome c-
mediated death. Consistent with this model, our results show that
increasing Apaf-1 levels overcame this XIAP inhibition and
rendered the myotubes sensitive to cytochrome c injections.
Endogenous Smac can overcome XIAP inhibition in
myotubes but not in cardiomyocytes
Despite this increase in resistance to apoptosis, myotubes
undergo apoptosis during development [12] and in response to
pathological stimuli [2]. Our experiments suggest that in order for
myotubes to undergo apoptosis, they would not only have to
release cytochrome c but also overcome the function of XIAP in
order to become competent to die. This could occur by decreasing
XIAP levels (Fig. 2b), upregulating Apaf-1 (Fig. 3d) or by
functional inactivation of XIAP (Fig. 2). There are several known
XIAP and Myotube Apoptosis
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are localized to the mitochondria. As structural studies have cast
doubts on the IAP inhibitory activity of HtrA2 [18], we focused on
Smac. Our data show that excess exogenous Smac is able to
permit cytochrome c-mediated apoptosis in myotubes (Fig. 2), but
whether the release of endogenous Smac is capable of doing so was
unknown.
To examine the importance of endogenous Smac in inhibiting
XIAP and permitting apoptosis, we took advantage of the
proapoptotic Bcl-2 family member tBid in order to release
Figure 1. Myotubes develop gradual resistance to cytosolic cytochrome c-induced apoptosis. (A) mC2C12 cells, dC2C12 cells
differentiated for 9 days and primary myotubes differentiated for 14 days, were injected with either yeast or bovine cytochrome c and rhodamine
dextran. (B) Photographs of mC2C12 and dC2C12 cells one hour following injection with yeast or bovine cytochrome c and rhodamine dextran.
Arrows point to injected cells. Scale bars represent 50 mm. (C) C2C12 cells differentiated for 6, 7 or 9 days (dd=days differentiated) were injected with
either yeast or bovine cytochrome c and rhodamine dextran. (D) Primary myotubes differentiated for 4, 11 or 14 days were injected with either yeast
or bovine cytochrome c and rhodamine dextran. Cell survival was assessed by morphology at the indicated times following injection. Data are the
mean6SEM of n$3 separate experiments per time point.
doi:10.1371/journal.pone.0005097.g001
XIAP and Myotube Apoptosis
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mitochondria (Fig. S1)[19]. Plasmids for tBid and GFP were
injected into dC2C12 cells and primary myotubes and survival was
assessed 24 hours later. Unlike cytochrome c injection, tBid
expression induced potent death in these cells. This death was
apoptotic as it was blocked with the pancaspase inhibitor Q-VD-
OPH (Fig. 4a, b). These data suggest that tBid is able to release
cytochrome c and presumably other mitochondrial factor(s) to
permit a caspase-mediated apoptotic death in myotubes.
To directly determine if endogenous Smac was responsible for
overcoming the function of XIAP in this tBid-mediated death, we
isolated myoblasts from Smac-deficient mice. Once differentiated,
we injected tBid and GFP into these myotubes. Unlike wildtype
myotubes, Smac-deficient myotubes were completely resistant to
tBid induced death (Fig. 4c). These results identify an important
role for endogenous Smac in myotubes and imply that if adequate
quantities of Smac were released from the mitochondria, this
would be sufficient to overcome the XIAP brake and allow
cytochrome c to induce myotube apoptosis.
We have previously reported that cardiomyocytes, like neurons
and myotubes, utilize the XIAP brake to inhibit cytochrome c-
induced apoptosis [16]. To determine if endogenous Smac is able
to inhibit XIAP and permit apoptosis in cardiomyocytes, isolated
neonatal rat cardiomyocytes were transfected with the tBid-GFP
plasmid and GFP or GFP alone. Six hours after transfection the
number of cells expressing active caspase 3 was determined by
immunohistochemistry. While 70 % of tBid transfected cardio-
myocytes showed active caspase 3 staining, this was seen in only 15
% of the GFP alone transfected cardiomyocytes (Fig. 5a).
Photographs in Fig. 5b show that tBid transfected cardiomyocytes
become rounded and died, whereas those in the presence of the
pan caspase inhibitor z-VAD-fmk survived. Together, these data
suggest that the release of cytochrome c and other mitochondrial
proteins by tBid, was sufficient to cause caspase activation and
apoptotic death in cardiomyocytes.
Next we determined if endogenous Smac was responsible for
allowing tBid to induce death in cardiomyocytes, as seen in
myotubes. Wildtype and Smac-deficient neonatal mouse cardio-
myocytes were infected with a tBid-GFP adenovirus. Infected cells
were examined by time-lapse microscopy over a 12 hour period.
As expected, tBid-GFP infected wildtype cardiomyocytes showed
only 20 % survival, and this death was blocked with the caspase
inhibitor z-VAD-fmk. Surprisingly, and in contrast to mytotubes,
Smac-deficient cardiomyocytes also showed only 23 % survival
when infected with tBid-GFP adenovirus. The death of the Smac-
deficient cardiomyocytes was apoptotic as it was completely
blocked by the addition of z-VAD-fmk (Fig. 5c). Western analysis
indicated that myotubes and cardiomyocytes expressed similar
levels of endogenous Smac despite the fact that myotubes could
utilize Smac to overcome XIAP whereas cardiomyocytes could not
(Fig. 5d). Levels of Smac were lower in sympathetic neurons
(Fig. 5d) which, like cardiomyocytes, do not appear to require
endogenous Smac to overcome XIAP [14,20].
Together, these data suggest that unlike myotubes, endogenous
Smac was not required for mitochondria-mediated death in
cardiomyocytes. In addition it suggests that there is likely to be an
additional mitochondrial factor in cardiomyocytes that is released
to allow XIAP to be overcome.
Discussion
Together, the data presented in this study identify that
postmitotic myotubes have increased suppression of their apoptot-
ic pathway relative to their mitotic precursors. Differentiated
C2C12 cells and primary myotubes were both resistant to cytosolic
cytochrome c due to the activity of endogenous XIAP (Fig. 1, 2).
However, myotubes inhibited caspase activation not by increasing
XIAP levels but rather by decreasing Apaf-1 (Fig. 3a, b, c).
Importantly, overexpressing Apaf-1 alone in dC2C12 cells, was
sufficient to allow cytosolic cytochrome c injection to kill dC2C12
Figure 2. Resistance to cytosolic cytochrome c is mediated by endogenous XIAP. (A) dC2C12 cells were injected with rhodamine dextran
and either bovine cytochrome c, wildtype AVPI-Smac, mutant MVPI-Smac or AVPI-Smac and cytochrome c together. (B) Primary wildtype (wt)
myotubes were injected with rhodamine dextran and bovine cytochrome c or AVPI-Smac and bovine cytochrome c. XIAP-deficient (XIAP-/-)
myotubes were injected with rhodamine dextran and either bovine or yeast cytochrome c. Cell survival was assessed by morphology at the indicated
times following injection. Data are the mean6SEM of n$3 separate experiments per time point.
doi:10.1371/journal.pone.0005097.g002
XIAP and Myotube Apoptosis
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this differential resistance between mitotic precursors and
myotubes. It is noteworthy to mention that a previous study
found that human skeletal muscle cytosol completely lacks Apaf-1
and therefore is refractory to cytochrome c-mediated caspase
activation [21]. This difference could be attributed to the different
model systems or the age of the skeletal muscle used, suggesting
that skeletal muscle continue to reduce Apaf-1 expression with age.
Based on these data, we propose that following cytochrome c
release from the mitochondria, the low levels of Apaf-1 present in
myotubes result in reduced apoptosome formation and caspase
activation. As a consequence, endogenous XIAP is sufficient to
effectively block this reduced level of caspase activation. However,
in mC2C12 cells, high levels of Apaf-1 result in robust apoptosome
formation, and thus, increased caspase activation that cannot be
successfully inhibited by endogenous XIAP. As a consequence,
these mitotic cells readily undergo apoptosis with cytosolic
cytochrome c while myotubes do not.
This increased resistance to apoptosis employed by myotubes is
strikingly similar to that found in other postmitotic cells,
specifically neurons and cardiomyocytes [14–16]. These findings
suggest that regardless of the function or phenotype of the cell,
postmitotic cells share the same features in restricting their ability
to undergo apoptosis. By requiring not only cytochrome c release
but also inhibition of XIAP function in order to activate caspases,
endogenous XIAP presumably serves as a safety brake to death.
For example, if the mitochondria accidentally release cytochrome
c, the presence of XIAP would block caspase activation and
Figure 3. Apaf-1 levels are decreased in myotubes. Restoring Apaf-1 is sufficient to allow cytochrome c-mediated death. (A) Levels of the
indicated apoptotic proteins were examined by Western blot of whole cell lysate from mC2C12 and dC2C12 cells. Tubulin serves as a loading control.
Densitometry of protein levels are normalized to loading control protein levels of the representative Western blot. (B) Levels of the indicated
apoptotic proteins were examined by Western blot of whole cell lysate from primary myoblasts and primary myotubes. Densitometry of protein
levels are normalized to loading control protein levels of the representative Western blot. (C) RT-PCR was carried out with primers for the indicated
mRNA using RNA from primary myoblasts and myotubes. GAPDH serves as a control. Densitometry of Apaf-1 mRNA levels are normalized to GAPDH
levels of the representative gel. (D) dC2C12 cells were injected with plasmids for either Apaf-1 (Apaf) or empty vector as well as GFP. 24 h following
injection, GPF positive cells were injected with rhodamine dextran and either yeast or bovine cytochrome c. Cell survival was assessed by morphology
at the indicated times following cytochrome c injection. Data are the mean6SEM of n$3 separate experiments per time point.
doi:10.1371/journal.pone.0005097.g003
XIAP and Myotube Apoptosis
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Arguably, increased resistance to caspase activation would be
critical to these postmitotic cells because of their inability to
replicate and their limited regenerative potential. These postmi-
totic cells also serve vital functions that require their presence for
the lifetime of the organism. On the other hand, not having this
resistance to apoptosis in mitotic cells is beneficial to the organism
as mitotic cells can give rise to cancer. Indeed, the mechanisms by
which the apoptotic pathway is inactivated in many cancers are
similar to those seen in postmitotic cells. For example, several
melanomas restrict their Apaf-1 expression at the transcriptional
level in order to block apoptosis [22–24]. In addition, many
chemoresistant cancers have been found to utilize XIAP to
effectively block caspase activation [25].
The XIAP-deficient mice lack an overt developmental pheno-
type [26]. This is consistent with our finding that myotube
apoptosis is dependent on the removal of the endogenous XIAP
brake as well as the release of cytochrome c. Neither event alone is
capable of activating caspases. However, the XIAP-deficient
myotubes are predicted to be more vulnerable if exposed to toxic
stimuli or injury that causes mitochondrial damage and cyto-
chrome c release, because they lack the postcytochrome c brake.
Figure 4. tBid causes caspase inhibitable death in myotubes that requires endogenous Smac. (A) dC2C12 were injected with plasmids for
tBid or empty vector as well as GFP in the presence or absence of Q-VD-OPH (QVD). GFP expressing cells were counted 8 h and 24 h following
injection. Percent survival was expressed as the percent of cells at 8 h that remained alive at 24 h following injection. Cell survival was assessed by
morphology. Asterisk indicates that the actual survival was 0 %. (B) Photographs of dC2C12 cells eight hours following injection with tBid and GFP in
the presence or absence of Q-VD-OPH (QVD). Arrows point to injected cells. Scale bars represent 50 mm. (C) Wild type (wt) and Smac-deficient
(Smac-/-) primary myotubes were injected as described and assessment of survival was the same as in (A). Asterisk indicates that the actual survival
was 0 %. Data are the mean6SEM of n$3 separate experiments per time point.
doi:10.1371/journal.pone.0005097.g004
XIAP and Myotube Apoptosis
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certainly circumstances in which myotubes activate caspases and
die. Caspase-mediated death has been observed during develop-
ment [12]. The role of apoptosis in pathological conditions is more
controversial. For example, several studies examining human
spinal muscular atrophy found that muscle fibers experience
apoptotic DNA fragmentation and the upregulation of apoptosis
associated factors [27–29]. On the other hand, a study utilizing
time-lapse microscopy to examine denervated and unloaded
muscle did not reveal any nuclei loss in muscle fibers, suggesting
apoptosis is not responsible for the loss of muscle mass experienced
during muscle atrophy [30]. Caspase-mediated death is thought to
be involved to some extent in additional pathological conditions
including muscular dystrophies and mitochondrial myopathies [2].
Figure 5. tBid induced apoptosis in cardiomyocytes does not require endogenous Smac. (A) Rat cardiomyocytes were transfected with
tBid-GFP or GFP alone. The percentage of transfected cells expressing active caspase 3 was determined 6 hours after transfection by
immunohistochemistry. (B) Photographs of rat cardiomyocytes 6 hours after transfection with tBid-GFP in the presence or absence of the caspase
inhibitor z-VAD-fmk (zVAD). (C) Wild type (wt) or Smac-deficient (Smac-/-) cardiomyocytes were infected with a tBid-GFP adenovirus in the presence
or absence of z-VAD-fmk (zVAD). Cell survival was determined by morphology over a 12 hour period using time-lapse microscopy. (D) Protein levels
of Smac were examined by Western blot of whole cell lysates from Smac-deficient dermal fibroblasts (Smac-/- DF), myotubes, cardiomyocytes and
sympathetic neurons (neurons). Tubulin serves as a loading control. Densitometry of Smac protein levels are normalized to tubulin levels of the
representative blot.
doi:10.1371/journal.pone.0005097.g005
XIAP and Myotube Apoptosis
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myotubes would not only have to cause the release of cytochrome c
but also inhibit XIAP. Here we identified three ways in which this
could occur. First, as XIAP-deficient myotubes are completely
sensitive to cytosolic cytochrome c (Fig. 2b), a stimulus which is
able to degrade or cleave XIAP and release cytochrome c would be
able to sensitize myotubes to apoptosis. In fact, selective XIAP
degradation has been seen in neurons undergoing apoptosis in
response to nerve growth factor withdrawal [14]. Second, dC2C12
cells overexpressing Apaf-1 became sensitive to cytochrome c-
mediated death (Fig. 3d). Therefore, a death stimulus which
increases Apaf-1 expression would also be able to overcome XIAP
inhibition. Supporting this idea, it has been shown that skeletal
muscle undergoing caspase activation due to metabolic deficien-
cies with ATP depletion and oxidative stress show an increase in
Apaf-1 levels [31]. Third, XIAP could also be functionally
inhibited in response to a death stimulus. This could occur
through several different mechanisms including an inactivating
posttranslational modification of XIAP or via an endogenous
inhibitor of XIAP. Here we show that releasing endogenous Smac
from the mitochondria is indeed sufficient to overcome XIAP and
allow cytochrome c to activate caspases in myotubes (Fig. 4c).
While the role of Smac as an IAP inhibitor has been extensively
characterized in vitro [9,10], the role of endogenous Smac has
remained elusive since most cells do not need to inhibit XIAP to
die [26,32]. While neurons and cardiomyocytes engage the XIAP
brake just like myotubes, one striking contrast between these
postmitotic cells is that neurons and cardiomyocytes do not appear
to utilize endogenous Smac to overcome XIAP (Fig. 5) [14,20].
The levels of endogenous Smac are much lower in sympathetic
neurons compared to myotubes (Fig. 5d). Therefore, it is possible
that neurons do not contain enough Smac protein to fully inhibit
XIAP. However, cardiomyocytes and myotubes have comparable
levels of Smac (Fig. 5d), suggesting that the reason endogenous
Smac is not effective in cardiomyocytes is not due to a lack of
protein altogether. Interestingly, other than myotubes, the only
cell type in which a role for endogenous Smac has been identified
is their precursor, myoblasts [8]. This raises the intriguing
possibility that endogenous Smac may play a vital role in this
particular myogenic cell lineage but not in other cell types.
It is intriguing that Smac-deficient cardiomyocytes are still able
to undergo tBid-induced death. This could be due to the release of
an additional mitochondrial factor in cardiomyocytes. Known
mitochondrial factors include AIF and HtrA2. AIF can be released
from the mitochondrial and cause death but AIF-induced death is
caspase independent [33] and therefore would not be blocked by
the addition of z-VAD-fmk. Structural data have cast doubt on the
IAP inhibitor function of HtrA2 [18], making it an unlikely
candidate as well. This raises the possibility that cardiomyocytes
contain an additional potentially novel mitochondrial factor that
can overcome XIAP when released.
The potential significance of the XIAP brake in myotubes can
be seen in mitochondrial encephalomyopathies, a group of
heterogeneous disorders due to mutations in either mitochondrial
DNA or nuclear genes. These mutations lead to mitochondrial
abnormalities which ultimately result in a decrease in ATP
synthesis and increased oxidative stress. Due to the heterogeneous
nature of these deficiencies even within the same patient, some
fibers appear healthy, some appear to suspend apoptosis and
others seem to die with active caspase 3 immunoreactivity
[31,34,35]. Many fibers from mitochondrial encephaolmypotha-
ties show clear Bax upregulation and cytochrome c release.
However, the number of fibers that show TUNEL staining is
much lower [31], suggesting that in these fibers cytochrome c is
released but cannot undergo caspase-mediated death. Our data
would predict that in these fibers, it is XIAP that is able to prevent
apoptosis despite the mitochondrial release of cytochrome c.A
potential role of endogenous Smac can be seen in vivo as well, in
patients with neurogenic muscular atrophy. In this condition,
where patients experience apoptotic muscle fiber loss, there is an
upregulation of multiple IAPs, including XIAP, but also Smac
which appears to become released into the sarcoplasm [36]. Our
findings would suggest that this release of Smac would be able to
overcome XIAP and allow the affected muscle fibers to die.
Materials and Methods
Reagents
All reagents were purchased from Sigma-Aldrich or Fisher
scientific, unless otherwise stated. Q-VD-OPH was purchased
from MP Biomedicals. Protease inhibitor cocktail was purchased
from Roche. XIAP-deficient mice were obtained from Dr. Craig
B. Thompson (University of Pennsylvania) and Smac-deficient
mice were obtained from Dr. Tak W. Mak (University of
Toronto). Our procedure for genotyping these mice has been
described previously [14,20]. All the work involving animals was
conducted using protocols approved by the Institutional Animal
Care and Use Committee at UNC Chapel Hill and carried out
under the regulations provided by the institutional body.
C2C12 cell line and primary myoblast cultures
C2C12 cell line was maintained in DMEM containing 20 %
FBS, 200 U/ml penicillin and 200 mg/ml streptomycin. When
C2C12 cultures reached 70–90 % confluency they were
differentiated by changing the media to differentiation medium
consisting of DMEM supplemented with 2 % horse serum, 200 U/
ml penicillin and 200 mg/ml streptomycin.
Satellite cell derived primary myoblasts were isolated from
lower hindlimb muscle from mice ranging in age from two to four
weeks old as described previously [37]. The primary cultures were
maintained on collagen-coated dishes in Ham’s F10 supplemented
with 20 % FBS, 2.5 ng/ml bFGF, 200 U/ml penicillin, 200 mg/ml
streptomycin, and 0.002 % Fungizone. The medium was changed
every other day and cultures were differentiated with the addition
of differentiation media when they reached 60–70 % confluency.
All experiments were performed using primary cultures that had
undergone between four and twelve passages. Experiments were
performed on dC2C12 cells following 9 days of differentiation and
on primary myotubes following 14 days of differentiation unless
otherwise indicated.
Primary cardiomyocyte cultures
Primary cardiomyocyte cultures were isolated from postnatal
day 0–1 mice or rats using the Worthington neonatal cardiomy-
ocyte isolation system (Worthington Biochemical Corp.) following
the manufacturer’s instructions. A 2 hour preplating step was
included to reduce the number of fibroblasts in the cultures. Cells
were then plated on laminin-coated MatTek 35 mm glass bottom
dishes for time-lapse imaging or laminin-coated 35 mm dishes for
transfection. Cells were grown in MEM with Earle’s salt
supplemented with 2 mM glutamine, 10 % horse serum, 5 %
FBS, 100 U/ml penicillin, and 100 mg/ml streptomycin.
Experiments were performed on rat cardiomyocytes 5 days after
plating and mouse cardiomyocytes 2 days after plating. Rat
cardiomyocytes were transfected with the indicated plasmid DNA
using Lipofectamine 2000 (Invitrogen) following the manufactur-
er’s instructions.
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Primary dermal fibroblasts were isolated from postnatal day 0
(P0) Smac-deficient mice. The dorsal skin was removed, minced
and rinsed in ice cold PBS. Tissue was then treated with 1 mg/ml
collagenase, followed by digestion with 2.5 mg/ml trypsin for 1
hour each at 37uC. Tissue was then passaged through a 25 gauge
needle until a single cell suspension was obtained. Cells were
plated in DMEM with 10 % FBS, 100 mg/ml penicillin, and 100
mg/ml streptomycin.
Primary sympathetic neuron cultures
Primary sympathetic neurons were isolated as described
previously [38]. Briefly, superior cervical ganglia were dissected
from P0 mice and treated with 1 mg/ml collagenase, followed by
2.5 mg/ml trypsin for 30 minutes each at 37uC. Cells were then
dissociated by passaging through a fire-polished pipet and plated
on collagen-coated dishes in MEM with Earle’s salts supplemented
with 50 ng/mL NGF, 10 % FBS, 2 mM glutamine, 100 mg/mL
penicillin, 100 mg/mL streptomycin, 20 mM flourodeoxyuridine,
20 mM uridine, and 3.3 mg/ml aphidicolin. Experiments were
performed on sympathetic neurons 5 days after plating.
tBid-GFP Adenovirus production and use
As mouse cardiomyocytes are difficult to transfect, we generated
an adenovirus expressing tBid-GFP. The recombinant virus Ad-
tBid-GFP generated is responsive to TetR regulation and can be
amplified in 293TREx cells without cytotoxicity. The MluI-XbaI
fragment of pcDNA4/TO (Invitrogen) containing the CMV
promoter with TetO was ligated into the MluI-NheI-digested
pShuttle2 (BD Bioscience) to create pShuttle2/TO. tBid-GFP was
PCR amplified with DraI-XbaI ends from a plasmid from Dr.
Douglas R. Green (St. Jude Children’s Research Hospital) and
cloned into pShuttle2/TO. Subsequent steps in generating the
recombinant virus were according to manufacturer’s instructions of
BD Bioscience Adeno-X Expression System. The purification
procedures and titer determination have been described [39]. In
brief, Ad-tBid-GFP virus was purified by CsCl density gradient
centrifugation. Viral titer was determined by an indirect immuno-
fluorescent assay specific for the viral 72-kDa E2 gene product and
definedas focus forming units (ffu) per ml. Neonatal cardiomyocytes
were treated with Ad-tBid-GFP with multiplicity of infection (MOI)
of 200 ffu per cell in a total volume of 100 ml for 3 hours before
flooding the dishes with additional media to begin live imaging.
Microinjection
Cells were plated on 35 mmdishes and microinjected with needles
pulled on a Flaming-Brown horizontal micropipette puller (Sutter
Instruments) using a Narashigi micromanipulator mounted on a
Leica inverted florescent microscope. Between 25 and 100 cells were
injected in each experiment. The microinjection buffer contained
100 mM KCl and 10 mM KPi, pH 7.4. For injections involving
plasmid DNA, cells were injected and allowed 24 hours to express
plasmid DNA prior to experimentation. DNA microinjections
contained 50 ng/ml enhanced GFP (Clontech) and 200 ng/mlo f
the indicated plasmid. Cytochrome c microinjectons contained 5
mg/ml rhodamine dextran to mark injected cells and 25 ug/ul
cytochrome c. Whereindicated, 1 mg/ml recombinantSmac protein
wasinjectedalongwith25ug/uLcytochromec.Followinginjections,
viable cells were identified as rhodamine positive and intact. Data
shown are mean6SEM of three independent experiments.
Quantitation of cell survival
Cell survival after any treatment was assessed by counting
clearly identifiable cells with intact morphology, whereas dead cells
atrophied and degenerated. Surviving cells in the culture were
counted and expressed as a percent of the number of cells in the 0
hour condition. This method of assessing survival correlates well
with other cell survival assays such as trypan blue exclusion and
staining with calcein AM [14].
Western blots
Western blots were performed as previously described [14].
Primary antibodies were as follows: anti-Apaf-1 (Alexis), anti-
XIAP (MBL), anti-Smac (R&D Systems) anti-alpha tubulin
(Sigma). Mouse/rabbit/goat/rat HRP conjugated secondary
antibodies were purchased form Pierce Chemical Co. Western
blots were developed using the ECL-Plus detection system
(Amersham Biosciences). Densitometry was performed using
ImageJ software (NIH) and normalized to loading control protein
levels of the representative Western blot.
Quantitative RT-PCR analysis
Our method of quantitative RT-PCR analysis is a modification
of a previously published protocol [40], where we substituted the
radioactivity-based detection method with a fluorescence-based
detection technique. Briefly, RNA was isolated from cells with
DNAeasy kit (Qiagen) using the manufacturer’s protocol. Equal
amounts of the RNA isolated at specific times after the specified
treatment was converted into cDNA with SuperScript II Reverse
Transcriptase (Invitrogen). One microliter of cDNA was the
template in a PCR using the following primer pairs:
APAF-1: Forward 59 GAG GCA CAA TGG ATG CAA AGG
39; Reverse 59 GGC TGC TCG TTG ATA TTG AGT GG 39
GAPDH: Forward 59 CCA TGG AGA AGG CTG GGG 39;
Reverse 59 CAA AGT TGT CAT GGA TGA CC 39
Preliminary experiments validated that the RT-PCR technique
was linear with respect to the amount of input RNA used for RT
and with respect to the amount of cDNA used for PCR in these
experiments. No product was amplified when water was used as
input for a PCR reaction. Results were repeated in at least three
independent RNA preparations. Levels were quantified using
SYBR Green I Nucleic Acid Gel Stain (Molecular Probes Inc.,
Eugene, OR) and scanning blots on a Typhoon scanner
(Amersham Biosciences). Densitometry was performed using
ImageJ software (NIH) and normalized to GAPDH levels of the
representative gel.
Image acquisition and processing
Images were acquired by a Hamamatsu ORCA-ER digital B/
W CCD camera mounted on a Leica inverted fluorescence
microscope (DMIRE 2). The image acquisition software was
Metamorph version 5.0 (Universal Imaging Corporation). Images
were scaled down and cropped in Adobe Photoshop to prepare the
final figures.
Live-imaging of cardiomyocytes
Cardiomyocytes were imaged by a Zeiss Pascal confocal
microscope in a live incubation chamber. Eight random regions
in the dish were selected to be repeatedly imaged every 6 minutes
for up to 12 hours. The survival of GFP-expressing neonatal
cardiomyocytes was assessed by cell morphology using the Zeiss
LSM image browser.
Immunohistochemical analysis
Immunohistochemical analysis was performed using the same
method as previously described [41]. Primary antibodies were as
follows: anti-cytochrome c (BD Biosciences) and anti-GFP (Upstate
XIAP and Myotube Apoptosis
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CY3-conjugated (Jackson Immunoresearch Laboratories Inc.) and
anti-chicken Alexa488-conjugated (Molecular Probes Inc.).
Supporting Information
Figure S1 tBid induces the release of cytochrome c from
mitochondria in differentiated C2C12 (dC2C12) cells. dC2C12
cells were injected with plasmids for tBid or empty vector, as well
as GFP, in the presence of the caspase inhibitor Q-VD-OPH (to
prevent cell death). 24 h after the injections, cells were
immunostained with an antibody to cytochrome c. Arrows point
to the injected cells. Control GFP alone expressing cells show
cytochrome c staining (upper panel) which is lost upon its release
from the mitochondria in tBid expressing cells (lower panel).
Found at: doi:10.1371/journal.pone.0005097.s001 (2.39 MB TIF)
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